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Pseudomonas aeruginosa is a Gram-negative bacterium commonly found 
throughout the environment. It is a significant cause of disease and mortality in 
immunodeficient patients such as those suffering from cystic fibrosis (CF). Due to the 
emerging antibiotic resistance of P. aeruginosa, it is becoming increasingly more 
challenging to treat an infection by traditional means. Further complicating treatment, P. 
aeruginosa secretes a protein known as Inhibitor of Vertebrate Lysozyme (PaIVY) that 
binds to and inhibits C-type lysozyme, thus preventing the degradation of the bacterium. 
A reactive chemical warhead was synthesized from a rhenium(I) tricarbonyl derivative in 
order to bind to and irreversibly inhibit PaIVY, thereby allowing endogenous host 
lysozyme to effectively degrade drug-resistant P. aeruginosa bacteria. Various 
biophysical methods, such as fluorescence spectroscopy, NMR, and mass spectrometry 
are utilized in the characterization of the rhenium(I) tricarbonyl derivative and the 
binding interaction PaIVY experiences when placed in the presence of the chemical 
warhead.    
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Chapter One 
Background and Significance 
Cystic fibrosis (CF) is an autosomal recessive genetic disorder that affects about 
70,000 people worldwide with 1,000 new cases annually.1 CF is a disorder of the 
exocrine glands that results from a mutation in the cystic fibrosis transmembrane 
conductance regulator protein-coding gene (CFTR). These mutations affect sodium and 
chloride ion transport at the apical surface level of exocrine gland epithelial cells. In 
healthy individuals, a thin, salt containing layer of mucus coats the surface of the 
respiratory tract, trapping debris and pathogens that will be swept out by cilia. For 
individuals with a mutation in the CFTR protein, the result is too little chloride transport 
and too much sodium transport. Due to the excess sodium, water is depleted from the 
secretions creating a thick mucus that accumulates in the lungs allowing for bacterial 
growth and infection.2 
Pseudomonas aeruginosa is an opportunistic bacterium widely found throughout 
the environment in soil and water. For healthy individuals an infection would be mild if 
established at all. However, for immune compromised individuals, or those suffering 
from CF, the infection is responsible for a high rate of morbidity and mortality.3 P. 
aeruginosa is one bacterium that finds home in the thick mucus secretions found in the 
respiratory tract of patients with CF. The bacterium produces a biofilm which is highly 
tolerant towards the host immune system and helps enable the pathogen to be up to 1,000 
times more tolerant to antibiotics.4 Further complicating matters, P. aeruginosa secrets a
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 protein known as Inhibitor of Vertebrate Lysozyme (PaIVY) from its periplasm. This 
protein inhibits C-type lysozyme that would normally compromise the structural integrity 
of the bacterial cell wall by catalyzing the hydrolysis of the β-1,4 glycosidic bond 
between N-acetylmuramic acid (NAM) and N-acetylglucosamine (NAG) that are the 
disaccharide building blocks of the peptidoglycan polymers in the bacterial cell wall5 
(Figure 1). Eradicating P. aeruginosa infection is increasingly more difficult due to its 
growing antibiotic resistance and production of PaIVY, producing a need for alternative 
treatment methods. 
 
Figure 1. Composition of the bacterial cell wall indicating lysozymes cleavage site; NAG 
and NAM are represented by the red and green hexagons, respectively, while peptide 
chains are indicated by the blue lines. 
 
 One target for inhibiting PaIVY is an exposed loop with H62 at the center that is 
involved in the inhibition of lysozyme (Figure 2). When PaIVY interacts with lysozyme 
the loop from PaIVY occupies the active site of lysozyme forming hydrogen bonds with 
two of the three residues, Aps52 and Glu35, involved in its enzymatic activity.7 
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Transition metals yield promising results for binding amino acids which could block this 
interaction from occurring.9 
 
 
Figure 2. Ribbon structure of PaIVY; shown in red is the exposed loop with H62 
indicated by a stick structure on the loop.8  
 
Metal complexes have re-emerged as enzyme inhibitors because of their structural 
diversity, adjustable ligand exchange kinetics, fine-tuned redox activity, and their distinct 
spectroscopic signatures.9 These metal complexes are used in biological systems by 
forming coordination bonds to residues at the protein surface or in the active site. A 
reactive warhead, or covalent inhibitor, contains a specific group that is designed to react 
with a target typically an amino acid side chain that is part of the catalytic activity by 
covalent binding. The covalent binding is much stronger than typically non-covalent 
interactions such as hydrogen bonds or salt bridges, therefore frequently resulting in an 
irreversible interaction.10 
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 Rhenium cations are increasing in interest due to the potential to be used as a 
radiological imaging agent or as a therapeutic radiopharmaceutical similar to technetium. 
There is a further interest in the coordination chemistry of rhenium complexes with 
biological molecules due to its potential to be used as a bifunctional chelating agent 
(BFCA) in drug designs.11 Rhenium(I) tricarbonyl molecules have been identified to bind 
to nucleic acids, nucleotides, polypeptides, and amino acids. Of particular interest 
Re(CO)3(H2O)3+ has been identified to form complexes with N-acetyl histidine and 
histidylhistidine, making it an ideal candidate to design a reactive warhead targeting H62 
of PaIVY.11 Furthermore, diamine rhenium tricarbonyl complexes are favored for their 
strong luminescence that can be used in characterization.12 Other techniques such as 
nuclear magnetic resonance, mass spectrometry, and X-ray crystallography are also often 
important in characterization and identification of these types of compounds and for 
monitoring complex formation to biomolecules.13, 22, 23 
 Nuclear magnetic resonance (NMR) has a growing role in the drug discovery 
process with the ability to identify binding sites, affinities, and ligand poses at the 
individual amino acid level without necessarily solving the structure of the protein-ligand 
complex.13 Heteronuclear single quantum coherence (HSQC) is a 2-dimensional NMR 
pulse sequence that is frequently used in protein chemistry. Using a 15N-labeled protein, 
an HSQC provides a fingerprint of the folded protein by showing a peak for each non-
proline amino acid in the backbone due to the variation in chemical environment each 
residue experiences. Once each peak is assigned, HSQC can be used to monitor protein 
interactions with any unlabeled ligand that is added to the protein solution and afford 
residue specific information about chemical changes. Chemical shift perturbation arises 
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from changes in the chemical environment the nucleus experiences from conformational 
changes induced by a binding event making HSQC a reliable source for identifying if 
binding of a reactive warhead occurs and at what amino acid residue(s).14 
 Other biophysical methods can be utilized to characterize complex formation 
including mass spectrometry and fluorescence. There is a wide range of mass 
spectrometry techniques that can be used for molecule characterization including matrix-
assisted laser desorption/ionization (MALDI), liquid chromatography-mass spectrometry 
(LC-MS), and electrospray ionization mass spectrometry (ESI-MS). ESI-MS is of 
particular interest for characterization of the warhead alone as well in complex with 
PaIVY because ESI-MS applications include protein-ligand binding experiments. ESI is a 
soft ionization technique that converts solution-phase analytes to gas-phase analytes and 
measures the mass-to-charge ratio (m/z).15 ESI-MS begins by introducing the sample to 
the ionization source in the mass spectrometer where the solution-phase analytes are 
converted to gas phase analytes using electrical energy and obtain a positive or negative 
charge. From here they arrive at the detector based on the m/z ratio. Once the ions are 
detected the signals are transferred to a computer which displays the information 
graphically providing a fingerprint for the compound.16 This information will be used to 
verify the identity of the synthesized warhead as well as identify where the warhead is 
interacting with PaIVY.  
The use of fluorescence in biological sciences for cellular and molecular imaging 
has grown rapidly because there is no longer the need for expensive and difficult to 
handle radioactive tracers while the  detection remains highly sensitive. 17 There are 
many different techniques in which fluorescence can be monitored to reveal valuable 
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information about a compound such as fluorescence resonance energy transfer (FRET), 
fluorescence polarization or steady state fluorescence. Steady state fluorescence is the 
most common type of fluorescence in which the sample is illuminated with a continuous 
beam of light and the intensity or emission spectrum is recorded.17 Fluorescence studies 
can be carried out on many rhenium compounds due to their distinct spectroscopic 
signatures depending on the different ligands attached and the solvent used. The distinct 
absorption and emission spectra the rhenium compound exhibits are highly useful in 
characterization and binding studies. One way fluorescence can be used in binding 
studies is by determining the rate of the reaction. Most proteins do not exhibit any 
fluorescence of their own, therefore by attaching a fluorescent molecule the rate at which 
the two react can be monitored.  
Another important technique that can be used in determining where a ligand is 
binding to a protein is site-directed mutagenesis using polymerase chain reaction (PCR). 
There are two types of site directed mutagenesis, simple or multiple mutations. A simple 
mutation method is based on the amplification of double‐stranded DNA from the 
template DNA using complementary oligonucleotides, or primers, carrying the mutation 
of interest while multiple mutations either obtain the mutation after several rounds of this 
process or can obtain them simultaneously in one reaction.18 In a PCR small amounts 
DNA are amplified or copied using a thermocycler. There are three steps to a PCR 
reaction: denaturation, where the DNA is heated and denatures becoming single-stranded, 
annealing where the primers, containing the mutation, bind to flanking regions of the 
DNA, and extension where DNA polymerase extends the 3’ end of each primer along the 
template strand.19 There are many commercially available kits for site directed 
  7 
mutagenesis that make the process simple as well as many useful websites to help design 
primers. For PaIVY, it was proposed that the H62 loop was the active site that binds to 
and inhibits lysozyme. Mutating this residue will help indicate if the residue is actually 
important in lysozyme inhibition as well as help indicate if the warhead is binding to this 
site.   
To determine if lysozyme is still active in the presence of an inhibitor such as 
PaIVY after site-directed mutagenesis or the addition of a reactive warhead a muramidase 
assay or a lysozyme activity assay is performed. This commercially available assay 
utilizes fluorescently labeled cells that indicate how active lysozyme is due to the 
relationship between the fluorescent signal recorded and activity of lysozyme being 
proportional.20 The fluorescent signal increases when lysozyme is properly functioning 
and lysing the cells. However, because PaIVY inhibits lysozyme the activity of lysozyme 
decreases and therefore the fluorescent signal also decreases as the concentration of 
PaIVY increases. This assay plays an important role in determining if the addition of the 
reactive warhead to PaIVY will eliminate or reduce PaIVY’s inhibition activity against 
lysozyme as well as determine if specific residues of PaIVY are necessary in the 
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Chapter Two 
Protein Purification and Mutagenesis 
 To begin research on the interactions between a reactive warhead and PaIVY 
purified protein must be available for use. Pseudomonas aeruginosa Inhibitor of 
Vertebrate Lysozyme (PaIVY) was purified following a protocol developed by Aaron 
Schultz, a previous graduate student, located in appendix two with some modifications. 
The original plasmid, PA3902, was purchased from DNASU in a pSpeedET vector with a 
six residue His tag containing a TEV cleavage site located at the beginning of the protein 
sequence. The plasmid has kanamycin antibiotic resistance.   
Following the protocol originally created by Aaron Schultz, the plasmid was 
transformed into BL21DE3PLysS single shot cells and onto kanamycin LB agar plates 
and left to grow overnight at 37°C. The following day, the transformed cells were used 
for an overnight culture. Typically for a 2 L prep, two 100 mL small inoculum flasks 
were prepared using LB media or M9 minimal media and left at 37°C overnight. The 
following day 50 mL from each flask would be transferred to 1 L flasks containing the 
respective media and left to grow to an OD600 of 0.6 at 37°C. Once the correct OD was 
reached the cells were induced using L-arabinose and left overnight at 37°C. The next 
day the cells were spun into a pellet, lysed using a French Press, and centrifuged again 
separating the crude lysate from the cell fragments.
 Subsequently the purification process consisted of an immobilized metal affinity 
chromatography (IMAC) His1 (Figure 3), followed by dialysis and TEV cleavage. The 
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His1 fraction is dialyzed for three hours to remove excess imidazole before TEV is added 
and then left overnight at room temperature. The following day a His2 (Figure 4) is 
performed and the peak fraction is concentrated down to approximately 2 mL. From this 
point the concentrated His2 peak is loaded on the size exclusion chromatography (SEC) 
column which will separate the protein by size (Figure 5) and therefore allowing for a 
pure sample of the protein of interest. In the outlined protocol the SEC is typically run in 
SEC buffer which consists of 20 mM monobasic potassium phosphate, 20 mM dibasic 
potassium phosphate and 200 mM potassium chloride at pH 8.0, however a modification 
using a new buffer from what Aaron previously used was adapted in order to save time 
on buffer exchange. The new buffer used to run SEC is 20 mM sodium phosphate buffer 
pH 6.0 or in sterile 18W water. Once the SEC was completed the peak at the appropriate 
place corresponding to the correct molecular size was collected and concentrated to the 
desired concentration. The concentration of the protein is dictated by the future 
experiments it will be used for. A typical two-liter preparation PaIVY yielded 
approximately 1.5 mL at 1.2 mM. After this the protein was aliquoted into smaller 
amounts, typically 500uL to be used for future experiments or frozen in the -80°C for 
later use. 
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Figure 3. His1 chromatogram of wild type PaIVY purification showing good separation 
between the 280 nm (green) and 255 nm (teal) wavelength in the elution phase indicating 
viable protein requiring further purification.  
 
 
Figure 4. His2 chromatogram of wild type PaIVY purification. After His tag has been 
removed showing good separation between the 280 nm (green) and 255 nm (teal) 
wavelength. 
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Figure 5. SEC chromatogram of wild type PaIVY purification. A symmetrical peak at 
the correct molecular weight for the protein of interest indicating pure PaIVY.  
 
 Performing site-directed mutagenesis on a protein has the potential to alter the 
purification protocol due to the potential loss or difference caused in the stabilization of 
the protein. H62 is the proposed active site of PaIVY making it an important target for 
site-directed mutagenesis. When the histidine residue is mutated valuable information can 
be gathered about the significance this residue plays in inhibition of lysozyme as well as 
its significance in binding to the reactive warhead. Initially site-directed mutagenesis was 
only intended to be performed for H62, however as data was collected via NMR studies 
about the warhead binding, further mutagenesis was performed on H20.  
Site directed mutagenesis was performed on PaIVY to further understand H62’s 
role in inhibition of lysozyme as well as its importance in warhead reactions. Previously, 
primers were originally designed by Aaron Schultz to mutate H62 to alanine, although he 
was never able to successfully obtain H62A before leaving. Site-directed mutagenesis 
was performed successfully by laboratory technician Sarah Waldron using these primers 
and following pfuUltra High-Fidelity DNA polymerase AD protocol.6 Once the correct 
  12 
mutation was successfully incorporated the DNA was transformed to DH5a cell line and 
mini-prepped to readily usable plasmid to be used in future experiments. When purifying 
H62A mutant protein the protocol was followed with the SEC buffer modification. H62A 
mutant typically did not express as well as wild-type PaIVY, usually only 0.5 mL at 1.2 
mM was collected per two-liter prep.  
It has been proposed that H62 is the active site of PaIVY in its inhibition of 
lysozyme and the proposed location that the warhead will bind, therefore mutating this 
residue should reduce or eliminate lysozyme inhibition, as well as no longer bind to the 
warhead. However, muramidase assays showed that H62A mutant still inhibits lysozyme 
and NMR studies showed that there is still chemical shift perturbation when the warhead 
is reacted with H62A mutant. The chemical shifts seen on the HSQC spectra for both 
wild-type PaIVY and the H62A mutant point to H20 as the possible alternative binding 
site. To further investigate this, new primers were designed to mutate H20.  
 Primers were designed using PrimerX. Once on the website the original plasmid 
sequence from DNASU of PaIVY was uploaded. Step two was left blank and for step 
three the primer design protocol drop-down menu was changed to QuickChange site-
directed mutagenesis kit by Stratagene. Initially the goal was to mutate His20 to alanine 
like H62 was, however there were no primers generated for alanine so various other 
amino acids were tried. On the next page, the plasmid sequence was copied to the box 
and the mutation was manually changed from CAT coding for histidine to GAT coding 
for aspartic acid. Once PrimerX generated primers for H20D these primers were copied 
and pasted into Oligo Calc to identify any hairpins, annealing points, and self-
complementary. Aspartic acid was chosen because it only required one nucleotide to be 
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changed and the primers designed contained one annealing site whereas many others had 
multiple annealing sites as well as a hairpin formation. Next the forward and reverse 
primers were ordered from idtDNA.  
 The primers were initially diluted to 100uM. Then following pfuUltra  High-
Fidelity DNA polymerase AD protocol, PCR was performed using wild type PaIVY as 
the template DNA for one PCR reaction. In a separate PCR reaction tube H62A mutant 
plasmid was used as the template DNA to get the H20D/H62A double mutant PaIVY 
with no other histidine’s in the sequence. Following a DNA gel was run on both sets of 
mutants and a band was seen indicating that the PCR worked. Next the DNA was 
transformed using DH5a cells and left to grow overnight on an LB agar kanamycin plate. 
Colonies from each plate were mini prepped to obtain the plasmid. E.Z.N.A Plasmid 
DNA Mini Kit II was used. The plasmid was eluted into 40uL sterile deionized water at 
219ng/uL and 150ng/uL for H20D and H20D/H62A respectively. The plasmid was then 
set for sequencing using Genewiz DNA Sequencing Services. 
 Protein purification was carried out following wild type PaIVY protocol to ensure 
the same protocol and buffers would work for the mutants. The original protocol worked 
for both mutants except during the dialysis and TEV cleavage. In the His2 spectrum there 
is a peak of uncleaved protein in the elution meaning not all of the His tag was cut off 
from the protein during the dialysis and TEV cleavage. The peak was not significantly 
large enough to do a second dialysis and TEV cleavage, but there likely needs to be a 
higher concentration of TEV added to the dialysis in order to cleave all of the protein. At 
the size exclusion chromatography (SEC) step, both mutants were run in the SEC buffer 
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initially because they were unlabeled and would not be used for NMR studies. Later the 
same modification of performing the SEC in other buffers was utilized for NMR studies.  
 
Figure 6. SDS-PAGE gel of H20D PaIVY and H20D/H62A PaVIY 
When sequencing arrived back, it was confirmed that the correct mutation was 
found on both. Moving forward, the next step was to purify the mutant proteins using 15N 
labeled ammonium chloride in M9 minimal media to use for NMR studies. When 
preparing samples for NMR, the only purification difference is that the SEC is run in 20 
mM sodium phosphate buffer at pH 6.0. to eliminate the need for  buffer exchange later. 
 
1    2     3    4.    5    6    7      8     9    10   11  12  13 
1. Ladder 
2. H20D His1 
3. H20D His2 
4. H20D SEC 
5. H20D/H62A His1 
6. H20D/H62A His2 
7. H20D/H62A SEC (Fraction 14) 
8. H20D/H62A SEC (Fractions 16-18) 
9. H20D/H62A SEC (Fractions 19-20) 
10. H62A 0.43mM 
11. H62A + [Re(CO)3(H2O)3]Cl+ (1) 
12. H62A + [Re(CO)3(Phen)H2O]Cl+ (3) 
13. Ladder  
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Chapter Three 
Designing a Warhead and NMR Spectrometry 
 Due to its ability to bind to amino acids and specifically its ability to bind N-
acetyl histidine and histidylhistidine residues such as the histidine-62  (H62) residue of 
PaIVY, the original warhead of focus is a rhenium(I) tricarbonyl complex. 
Re(CO)3(H2O)3+ (1) was found to bind to His15 of Hen Egg White Lysozyme (HEWL)8 
sparking the idea that it would also be an ideal candidate for a reactive warhead targeting 
the exposed H62 loop on PaIVY. To begin testing this hypothesis [Re(CO)3(H2O)3]Br+ 
(1) was synthesized following the published protocol by Lazarova et al.24 in which 
Re(CO)5Br+ or Re(CO)5Cl+ was refluxed for several hours with water to produce 
[Re(CO)3(H2O)3]Br+ (1) (Figure 7). After the reaction was refluxed to completion, the 
product containing solution was transferred to a 50 mL falcon tube and placed in the -
80°C freezer overnight. The following day the frozen solution was lyophilized for 24 
hours. The product was a tan/white, flakey solid that is easily soluble in water. Once 
[Re(CO)3(H2O)3]Br+ (1) was synthesized, a stock solution in water was made at 100 mM 
concentration which would be used in following experiments. 
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Figure 7. Structure of Re(CO)3(H2O)3+ (1) 
 To test the viability of this warhead (1), the stock solution of [Re(CO)3(H2O)3]Br+ 
(1)was combined with 15N labeled PaIVY, purified by adapting a prior student’s, Aaron 
Schultz’s, protocol as described in appendix two, to monitor any binding interactions 
using an HSQC program on the Bruker 400 MHz NMR located at Kennesaw State 
University. The NMR spectra were all processed using NMRPipe and analyzed with 
SPARKY.  
Several experiments were performed initially to gauge how much of the warhead 
(1) would be necessary and at what time point the reaction between [Re(CO)3(H2O)3]Br+ 
(1) and PaIVY was completed. To test this, 1.25 mM 15N PaIVY was reacted with the 
warhead (1) at 5x molar equivalents and monitored at time zero, 24 hours, 72 hours, and 
seven days incubation time. At a high concentration of 15N PaIVY and 5x excess warhead 
(1) with a short incubation time of 24 hours, it was found that many of the previously 
visualized amino acids peaks from the reference 15N HSQC of PaIVY containing no 
warhead were no longer present after reacting with [Re(CO)3(H2O)3]Br+ (1) (Figure 8). 
This result demonstrated some of the limitations of using NMR. One drawback of using 
NMR is that high molecular weight species are not visible. However, the addition of just 
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become too large and no longer visible. From this is was speculated that multiple protein 
molecules were interacting with one warhead (1) and creating a dimer or trimer-like 
complex that would have a much higher apparent molecular weight with broader 
lineshapes that would make the protein difficult to observe by solution NMR. 
 
Figure 8. Reference HSQC of 15N PaIVY at 1.23 mM with no warhead(red) overlaid 
with few residual peaks from 1.25 mM 15N PaIVY reacted with five equivalents of 
[Re(CO)3(H2O)3]Br+ (1) (blue) both in 20 mM sodium phosphate buffer pH 7.4. Due to 
the disappearance of the peaks, i.e. linebroadening, it is proposed that there is likely high 
molecular weight species being formed that limit NMR visibility of the compound.  
 
  To further investigate this phenomenon, a size exclusion chromatography (SEC) 
experiment that separates species based on their molecular weight was applied to the 
NMR sample (Figure 9). Interestingly the SEC showed three to four new peaks eluting 
between 50 and 62 mL whereas purified monomer IVY elutes at 69 to 72 mL. These 
additional peaks indicate multiple species of higher molecular weight which 
corresponded to dimers, trimers, and other oligomers of PaIVY that are formed in the 
presence of the warhead (1). This was then confirmed with an SDS-PAGE protein gel 
(Figure 10). In the last four lanes it can be seen that there are two additional bands at 
higher molecular weight confirming oligomerization. The SEC also showed that at this 
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high concentration the formation of the trimer-like complex and dimer was favored over 
the monomer which can be seen by the significantly higher peak on the SEC for the 
higher molecular weight species.  
 
Figure 9. Size exclusion chromatography (SEC) spectrum of 1.25 mM PaIVY reacted 
with five equivalents of [Re(CO)3(H2O)3]Br+ (1) in 20 mM sodium phosphate buffer at 
pH 7.4. Peaks labeled corresponding to fractions collected and run on SDS-page gel in 
Figure 10. Peaks 1/2 correspond to oligomers of PaIVY. Peak 3 corresponds to the 
monomer peak of PaIVY.  
 
 
Figure 10. SDS-PAGE protein gel using various conditions to show PaIVY is present in 
higher molecular weights than usual indicating one [Re(CO)3(H2O)3]Br+ (1) is 
coordinating to multiple PaIVY molecules. Boiling causes the oligomers to dissociate 




2. PaIVY heated 
3. Peak 1/2 heated 
4. Peak 3 heated 
5. Peak 1/2 heated, BME 
6. Peak 3 heated, BME 
7. PaIVY heated, BME 
8. PaIVY unheated 
9. Peak 1/2 unheated 
10. Peak 3 unheated 
11. Peak 1/2 unheated, BME 
12. All peaks unheated, BME 1      2     3     4     5     6      7      8      9    10   11   12  
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 Due to the formation of these higher molecular weight species the warhead was 
redesigned to stop the coordination of multiple PaIVY molecules to the rhenium 
warhead. A rhenium tricarbonyl complex was still the primary focus for a warhead but 
there needed to only be one site for the complex to coordinate to PaIVYs histidine 
residue, i.e. only one easily exchangeable water ligand, in order to prevent the formation 
of dimers and trimers. From this criterion the ideal warhead contains rhenium(I) at the 
center coordinating to three carbonyls and a bidentate ligand such as phenanthroline or 
bipyridine that leaves one rhenium coordination site free and able to coordinate to H62 of 
PaIVY. Re(CO)3(Phen)+ (2-4) became the focus of the new warhead design. Figure 11 
shows a representation of how the warhead (2-4) is intended to coordinate to H62 of 
PaIVY. 
  
Figure 11. Schematic of Re(CO)3(Phen)+ (2-4), shown in black, coordinating to a 
histidine, shown in blue. 
 
 Re(CO)3(Phen)X+ was synthesized in two ways. Initially, [Re(CO)3(H2O)3]X+ (1) 
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warhead (2,3). Previously synthesized [Re(CO)3(H2O)3]X+ (1) was mixed with 1,10 
phenanthroline in a 1:1.1 molar ratio in a round bottom flask containing acetone at room 
temperature with stirring to form [Re(CO)3(Phen)H2O]Br+ (2). The solution immediately 
turned bright yellow supporting product formation. Next, the mixture was moved to a 50 
mL falcon tube and left open to evaporate the acetone over the next few days until a fine 
yellow powder was left. Another variation of this same warhead is 
[Re(CO)3(Phen)H2O]Cl+ (3) in which Re(CO)5Cl is the starting material instead of 
Re(CO)5Br. The reaction is carried out in the same way with a difference being the 
halogen ion that remains in solution as well as the option to carry it out in a H2O solution 
containing purified protein in the second step.  
 A more efficient protocol published by Chakraborty et al.12 was discovered which 
required a one-step process. Since this protocol was one-step the remaining H2O on the 
warhead from the previous protocol was replaced with a Cl because the starting material 
is Re(CO)5Cl. The H2O from the previous protocol and the Cl from the new protocol 
would be replaced when  reacted with PaIVY. A comparison of all the warheads 
synthesized and their structural differences can be seen in Figure 12 and Figure 13. The 
synthesis required one molar equivalent of Re(CO)5Cl to be mixed with 1,10-
phenanthroline in chloroform and methanol and then refluxed for 24 hours to create 
Re(CO)3(Phen)Cl+ (4). The product was then vacuum filtered and left to dry for several 
days leaving a fine yellow powder.  
  21 
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Figure 13. Reaction schemes of each warhead used. 2 and 3 made in the two-step process 
involving Re(CO)3(H2O)3+ differing only in the halogen ion present. Warhead 4 made in 
the one-step process. 
 
 Once both identities were confirmed, the focus of the warhead became 
Re(CO)3(Phen)Cl+ (4) because it was easily produced by the one-step synthesis. To test 
the viability of the new warhead (4) design, several 15N HSQC NMR experiments were 
performed in order to find the ideal incubation time of the reaction to reach completion as 
well as how much excess of the warhead (4) would be necessary. 1.06 mM purified 15N 
PaIVY was reacted with one, three, and five molar equivalents of warhead (4). It was 
monitored using the 400 MHz NMR located at KSU at time zero, 24 hours, 72 hours, 
seven days, and 10 days. Each of the different concentrations showed no changes at time 
zero, little to no changes at 24 hours (Figure 14), and many slight changes after three 
days (Figure 15). The 15N HSQC showed some chemical shift perturbation, but it was 
not as significant as expected. It was speculated that due to the low solubility of 
phenanthroline in water that not enough of the warhead (4) was in solution to show a 
significant chemical change on the NMR. Unfortunately, there is little to change about 
the buffer solution containing PaIVY in order to improve solubility of the warhead (4) 
due to the protein’s need to be in an aqueous environment or risk denaturation. In an 
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was reduced from 7.4 to 6. Unfortunately, this did not significantly change the solubility 
of the warhead (4), so a new technique needed to be adapted in order to achieve the 
complex formation between the warhead (4) and PaIVY. 
  
 
Figure 14. Overlay of the reference 15N HSQC at 1.23 mM (red) and 1.06 mM PaIVY 
reacted with three equivalents of [Re(CO)3(Phen)H2O]Br+ (2)after 24 hours incubation 
(blue). No chemical shift perturbations noted. 
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Figure 15. a.) Overlay of the reference 15N HSQC at 1.23 mM (red) and 1.06 mM PaIVY 
reacted with three equivalents of [Re(CO)3(Phen)H2O]Br+ (2) after three days incubation 
(blue). Labels in yellow indicate some of the notable chemical shift perturbations. b.) 
Zoomed in image from Figure 11 to show the slight chemical shifts noted in yellow. 
 
Due to the solubility issue, it was later decided to do the reaction in two parts. 
First allow a two times excess of [Re(CO)3(H2O)3]X+ (1) to react with purified PaIVY at 
a. 
b. 
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a low concentration, about 0.5 mM, for two days and then add an excess of 
phenanthroline into the reaction tube to react for an additional two days. The solution 
began turning yellow after the first 24 hours and increased in intensity by the 48 hours 
reacting at room temperature. The color after 48 hours can be seen in Figure 16. The 
reaction was then loaded on the SEC column and the monomer peak was collected 
(Figure 17), concentrated to 0.5 mM and subsequently an HSQC NMR was performed 
using the 600 MHz NMR located at KSU. It can be seen that doing this reaction at a 
lower concentration than previously favored the formation of the monomer peak rather 
than a trimer or dimer (Figure 18). The HSQC spectra showed promising results of 
chemical shift perturbation however, many of the peaks were split indicating that not all 
of the PaIVY was in complex with the warhead (3). Another interesting discovery was 
that majority of the amino acid residues that experienced a shift were not located near 
H62 as expected but rather near H20 (Figures 18 and 19).  
 
Figure 16. Reaction tubes after 1,10-phenanthroline was added to PaIVY reacted with 
[Re(CO)3(H2O)3]X+ (1) indicating the formation of the warhead (3) due to the yellow 
color.  
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Figure 17. Size exclusion chromatography (SEC) of [Re(CO)3(Phen)(H2O)]Cl+ (3) 
reacted with PaIVY  
 
 
Figure 18. 15N HSQC spectra of monomer peak from SEC of [Re(CO)3(Phen)(H2O)]Cl+ 
(3) reacted with PaIVY at 0.3 mM in blue. Reference HSQC in red at 1.06 mM PaIVY 
after 72 Hr.  
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Figure 19. Surface crystal structure of PaIVY.8 In green are the amino acid residues with 
the most chemical shift perturbation after reacting with the warhead (3). The rest of the 
amino acid residues are in red. H20 shown in blue. H62 is shown in yellow.  
 
 To investigate further that H62 is not the warhead (3) binding site site-directed 
mutagenesis was performed and more NMR studies were done. Using the same technique 
of reacting purified 15N PaIVY with [Re(CO)3(H2O)3]X+ (1) then adding 1,10-
phenanthroline and SEC purifying the sample, 15N HSQC was performed at 600 MHz. As 
it was suspected, the H62A mutant PaIVY still had chemical shift perturbation when it 
was reacted with the warhead (3) (Figure 20). This indicated that H62 was not the 
binding site for the warhead (3). Additionally, an SDS-Page gel was run that indicated the 
H62A mutant was also forming dimer/trimers with PaIVY indicating the warhead (3) was 
reacting with H62A (Figure 21). In order to uncover if the warhead (3) was binding to 
H20 instead site-directed mutagenesis was performed for a second time.  
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Figure 20. a.) H62A reference in red at 200uM in a 300 mm tube overlaid with H62A 
reacted with [Re(CO)3(Phen)(H2O)]Cl+ (3) in blue at 0.5 mM in a 5 mm tube. This 
indicated the warhead (3) is still binding to PaIVY without H62 present. b.) Zoomed in 
view to see chemical shift perturbation. 
a. 
b. 
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Figure 21. SDS-PAGE gel image of wild type PaIVY and H62A mutant at different 
stages of soaking with the warhead (1,3).  
 
 The next step in figuring out if the warhead (3) was binding to H20 instead was 
site-directed mutagenesis to H20D. A single mutant and a double mutant removing both 
histidine residues in PaIVY was made. Next both of these mutants were reacted with the 
warhead (3) using the same technique and subject to NMR using the 600 MHz located at 
KSU. The HSQC spectra of the H20D and H20D/H62A mutants do not contain amino 
acid labels because the spectra were altered when the mutations were made requiring the 
need for three-dimensional NMR analysis to locate the residues and apply appropriate 
labeling that was not done. The HSQC spectra of the H20D mutant showed little to no 
chemical shift perturbation but rather broadening. This is most clearly noticed on residues 
G38 and S39 (Figure 22). These two residues were also affected when wild type PaIVY 
as well as H62A mutant was reacted with the warhead (3). This indicates that 
[Re(CO)3(Phen)(H2O)]Cl+ (3) is still binding to H20D mutant PaIVY but not as widely as 
previously. One explanation for this is a conformational change may be occurring when 
the warhead (3) binds. To  further investigate this the H20D/H62A double mutant was 
1. Ladder 
2. PaIVY 0.5mM 
3. PaIVY w/ Re(CO)3(H2O)3 0.38mM 
4. PaIVY monomer SEC peak 0.38mM 
5. PaIVY dimer SEC peak 0.38mM 
6. PaIVY trimer SEC peak 0.38mM 
7. PaIVY w/ Re(CO)3(H2O)3 0.35mM 
8. PaIVY w/ Re(CO)3(Phen)Cl+ 0.35mM 
9. PaIVY monomer SEC peak 0.35mM 
10. H62A PaIVY w/ Re(CO)3(H2O)3 0.4mM 
11. H62A PaIVY w/ Re(CO)3(Phen)Cl+ 
0.4mM 
12. H62A PaIVY monomer SEC peak 
0.4mM  1      2      3     4      5      6       7      8       9      10    11    12 
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also subject to a reaction with the warhead (3) and an HSQC was performed. This NMR 
spectra showed no chemical shift perturbation indicating that the warhead (3) was not 
binding to any other residue on PaIVY (Figure 23). This confirms that there is likely a 
conformational change happening when the warhead (3) binds that involves both the H20 
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Figure 22. a.) Reference HSQC of H20D at 1.2 mM in red overlaid with H20D reacted 
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Figure 23. a.) Reference HSQC of H20D/H62A double mutant at 1.4 mM in red overlaid 
with H20D/H62A reacted with the warhead (3) at 0.48 mM in blue. b.) Zoomed in image.  
a. 
b. 
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Chapter Four 
Muramidase Assay of Wild Type and Mutant PaIVY with and without the 
Warhead 
A muramidase assay is a lysozyme activity assay in which the ability of lysozyme 
to lyse cells is monitored using fluorescence when in the presence of PaIVY. In the assay 
lysozyme activity is measured on Micrococcus lysodeikticus cell walls which are 
fluorescently labeled to allow for quantification of the cells being lysed. The cells are 
labeled in such a way that the fluorescence is suppressed when the cells are lysed. The 
catalytic activity of lysozyme combats this quenching causing an increase in the 
fluorescent signal detected when it is properly functioning. The fluorescent signal 
detected is proportional to the activity of lysozyme20 making this assay extremely useful 
in determining if certain residues in the protein sequence are important or necessary for 
the inhibition of lysozyme as well as indicate if the addition of a reactive warhead (3) will 
prevent PaIVY from inhibiting lysozyme. In this assay Hen Egg White Lysozyme 
(HEWL) is used. It is expected that when wild type PaIVY is placed in the presence of 
lysozyme the cells fluorescence signal will decrease due to PaIVY’s ability to inhibit 
lysozyme and therefore prevent lysing of the cells. This can be seen in Figure 24.  
Each muramidase assay was performed using Enzcheck Lysozyme Assay Kit (E-
22013).20 The DQ cells were prepared following this protocol, however the lysozyme 
provided in the kit was not used but rather HEWL purchased from Hampton Research 
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and was prepared by making a 5 mM stock solution. Each assay was prepared using 
Corning 96 well black polystyrene plates with a clear bottom. For each muramidase 
performed 25uL of HEWL was used in each well, a varying amount of PaIVY was used 
based on the original concentration of the protein, a varying amount 1X reaction buffer to 
bring the volume of PaIVY and 1X reaction buffer to 25uL total and lastly each well 
contained 50uL of fluorescently labeled DQ cells. The total volume used in each well 
was 100uL. The exact amounts used in each well for each reaction can be seen in Tables 
1 and 2. DQ cells were always added last to ensure the each well reaction started at 
approximately the same time. Once each well had the proper amount of each component, 
the plate was placed in darkness and left for 30 minutes until the fluorescent signal was 
measured using the Synergy H1 fluorescent plate reader. The plate reader was set to an 
excitation of 485 nm and emission scan at 530 nm and the background fluorescence was 
subtracted using the blank.  
 
Figure 24. Muramidase assay of wild type PaIVY at various concentrations in the 
presence of 100 nM hen egg white lysozyme (HEWL).  













Concentration of Wild Type PaIVY  Vs. Percent Lysis 
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The proposed active site of PaIVY’s inhibition of lysozyme is the exposed H62 
loop, therefore it was hypothesized that when H62 is mutated to H62A there would no 
longer be a decrease in the fluorescence signal in the assay because lysozyme would be 
free to effectively lyse the cells. Once the H62 residue of PaIVY was correctly mutated to 
alanine, a muramidase assay using the mutated protein was performed following Table 1 
concentrations. Interestingly, the H62A mutant behaved almost identical to wild type 
IVY when in the presence of lysozyme. This is indicated by the fluorescent signal 
decreasing as the concentration of PaIVY increased  (Figure 25). The decreasing 
fluorescence recorded with increasing concentrations of PaIVY in combination with BLI 
data collected by another graduate student Amani Gaddy, indicated the H62A mutant still 
binds lysozyme only slightly weaker than wild type IVY disproved the hypothesis that 
H62 is responsible solely for the inhibition of lysozyme.  
  
Figure 25. Muramidase assay of H62A mutant PaIVY at various concentrations in the 
presence of 100 nM hen egg white lysozyme (HEWL).  
 
 












Concentration of H62A Mutant PaIVY  Vs. Percent Lysis 
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Table 1. Concentrations of each IVY used in the free protein muramidase assays in 
Figures 24, 25, 28, and 29.  
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Table 2. Concentrations of each IVY reacted with the warhead (3) used in muramidase 
assays for Figures 26, 27, 30, and 31. 
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Additionally, it was hypothesized that the addition of the warhead (3) to PaIVY 
would block the H62 residue from being able to interact with lysozyme and thus allowing 
lysozyme to effectively lyse the cells. Muramidase was performed using warhead (3) 
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reacted PaIVY samples reacted using the same technique as previously described for the 
NMR experiments of reacting purified PaIVY with [Re(CO)3(H2O)3]X+ (1) then adding 
phenanthroline and SEC purifying the sample. Curiously, there was not a significant 
difference between the free protein in the presence of HEWL as there was with the 
warhead (3) reacted protein (Figure 26). Similarly, the H62A mutant showed no 
significant difference between the free protein and the warhead (3) reacted protein in the 
presence HEWL (Figure 27). This indicated for both wild-type PaIVY and H62A mutant 
PaIVY that either the warhead (3) was not binding to the correct site for inhibition, or 
that there was still too much unreacted protein available to inhibit lysozyme. 
 
Figure 26. Muramidase assay of wild type PaIVY at various concentrations in the 
presence of 100 nM hen egg white lysozyme (HEWL) in blue and wild type PaIVY 
reacted with an excess of the warhead (3) at various concentrations in the presence of 100 
nM HEWL. 













Concentration of Wild Type PaIVY Vs. Percent Lysis
100nM HEWL
100nM HEWL with 
Warhead
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Figure 27. Muramidase assay of H62A mutant PaIVY at various concentrations in the 
presence of 100 nM hen egg white lysozyme (HEWL) in blue and wild type PaIVY 
reacted with an excess of the warhead (3) at various concentrations in the presence of 100 
nm HEWL. 
 
Based off of the NMR studies done previously, it was indicated that H62 was 
likely not the binding site for the warhead (3) but rather H20. Once the H20D and 
H20D/H62A mutants were successfully expressed, a muramidase assay was done in order 
to see if these mutations alone or the addition of the warhead (3) affected PaIVY’s ability 
to inhibit lysozyme. The muramidase assay showed almost identical curves for both the 
free H20D and H20D/H62A mutant proteins when in the presence of 100 nM HEWL in 
which the fluorescent signal diminished as the concentration of PaIVY increased 
(Figures 28 and 29). This indicated that the H20D mutation was not important in the 
inhibition of lysozyme and that removing both histidine residues from PaIVY also did not 
affect the inhibition of lysozyme making it all the more pertinent that the warhead (3) 
blocks the interaction between PaIVY and lysozyme. 












Concentration of H62A Mutant PaIVY  Vs. Percent Lysis 
100nM HEWL
100nM HEWL with 
Warhead
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Figure 28. Muramidase assay of H20D mutant PaIVY at various concentrations in the 
presence of 100 nM hen egg white lysozyme (HEWL). 
 
 
Figure 29. Muramidase assay of H20D/H62A mutant PaIVY at various concentrations in 
the presence of 100 nM hen egg white lysozyme (HEWL). 
 
H20D and H20D/H62A PaIVY mutants were reacted with the warhead (3) using 
the same technique as previously described for other experiments and a muramidase 
assay was performed. For both the H20D and H20D/H62A mutant proteins reacted with 
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the warhead (3), the muramidase assay showed no inhibition. The curve of the warhead 
(3) reacted proteins followed along in a similar fashion as that of the free protein 
(Figures 30 and 31). It is to be noted that at a concentration of 0.3uM PaIVY for wild 
type and each mutant protein the warhead (3) reacted proteins exhibited a higher percent 
lysis. This could indicate that the warhead (3) is making the reaction slower between 
PaIVY and lysozyme, but the interaction is not strong enough to fully prevent PaIVY 
from inhibiting lysozyme. When the warhead (3) reacted PaIVY is SEC purified the 
monomer peak is collected, however because there is not a large discrepancy in 
molecular weight of that of free PaIVY and warhead (3) attached PaIVY, the peak 
collected could contain both free and reacted protein. Therefore, the similar muramidase 
curves could also indicate that there is too much free PaIVY that did not react with the 
warhead (3), that is free to interact and inhibit the lysozyme.  
 
Figure 30. Muramidase assay of H20D mutant PaIVY at various concentrations in the 
presence of 100 nM hen egg white lysozyme (HEWL) in blue and wild type PaIVY 
reacted with an excess of the warhead (3) at various concentrations in the presence of 100 
nm HEWL. 
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Figure 31. Muramidase assay of H20D/H62A mutant PaIVY at various concentrations in 
the presence of 100 nM hen egg white lysozyme (HEWL) in blue and wild type PaIVY 
reacted with an excess of the warhead (3) at various concentrations in the presence of 100 
nM HEWL. 
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Chapter Five 
Fluorescence and Mass Spectrometry Studies 
Fluorescence is a useful tool in characterizing and studying fluorescent molecules. 
Re(CO)3(Phen)Cl+ (4) is a fluorescent molecule with an excitation at 370 nm and 
emission at 605 nm according to Chakraborty et al12. Because three of the four warheads 
are fluorescent molecules their fluorescent properties can help indicate whether PaIVY is 
reacting with the warhead and help determine the rate of the reaction. When the 
fluorescence was initially being investigated warhead 2 was used for these studies.   
[Re(CO)3(Phen)H2O]Br+ (2), [Re(CO)3(Phen)H2O]Cl+ (3), and Re(CO)3(Phen)Cl+ 
(4)  each fluoresce, so fluorescence studies were performed to investigate binding to 
PaIVY. First using Corning black polystyrene 96-well plates with a clear bottom various 
concentrations of [Re(CO)3(Phen)H2O]Br+ (2) and PaIVY solutions were monitored over 
the course of one week as well as individual solutions of just PaIVY and 
[Re(CO)3(Phen)(H2O)]Br+ (2) for comparison. Using Biotek Synergy H1 an excitation 
and emission scan were collected. Initially a fixed excitation was set at 370 nm and 
emission at 600 nm based off literature values. It was noted that the wavelength 
corresponding to the excitation and emission may fluctuate based on the solution the 
compound is in as well as each molecule attached. Later the excitation and emission 
values were shifted to 370 nm and 520 nm respectively in order to get a more accurate 
reading based on previous scans. Interestingly the warhead (2) complex with PaIVY 
surpassed the fluorescent signal of just [Re(CO)3(Phen)H2O]Br+ (2) alone (Figure 32).
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 Being that PaIVY does not fluoresce on its own it was proposed that when the warhead 
(2) is mixed with PaIVY the binding between the two causes more 
[Re(CO)3(Phen)H2O]Br+ (2) to be pulled into solution and therefore the fluorescent 
signal increases. This is plausible because the warhead (2) alone is poorly soluble in the 
20 mM pH 6 sodium phosphate buffer in which PaIVY is stored. The fluorescence 
studies also indicated that the complex formation between the warhead (2) and PaIVY is 
time dependent reaching a maximum around day 4 and that the reaction is temperature 
dependent as well. When the same experiment was conducted at 4°C versus the usual 
25°C, the fluorescence did not increase over time indicating that PaIVY was likely not 
binding the warhead (2). The growing fluorescence signal provided a preliminary kinetics 
curve following second order kinetics (Figure 33). All of the fluorescent plate studies 
were done using [Re(CO)3(Phen)H2O]Br+ (2) because at the time of the experiments the 
one-step process to produce Re(CO)3(Phen)Cl+ (4) had not yet been discovered.  
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Figure 32. Excitation and emission spectra of free [Re(CO)3(Phen)H2O]Br+ (2) and in 
complex with PaIVY at 0.5 mM in 20 mM sodium phosphate buffer at pH 6. 
 
 
Figure 33. Intensity vs time for 1 mM and 0.1 mM PaIVY and [Re(CO)3(Phen)H2O]Br+ 
(2) 
 
 Another useful technique to monitor intact proteins and their complexes is 
electrospray ionization mass spectroscopy (ESI-MS) because it preserves the protein 
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folding and its covalent interactions. The goal of performing ESI-MS was to determine if 
the warheads were binding to PaIVY. When doing ESI-MS a raw spectrum is provided 
from which the mass and charge can be calculated . If any of the warheads are binding to 
PaIVY there will be a shoulder peak on the spectrum that corresponds to the mass of 
PaIVY plus any adduct. For ESI-MS each sample was prepared following the 
specifications outlined in Table 3 and sent to the University of Georgia’s Proteomics and 
Mass Spectrometry facility where the samples were run on the Bruker Esquire 3000 Plus 
Ion Trap Mass Spectrometer equipped with an ESI ion source.  
Table 3. Electrospray Ionization Mass Spectroscopy (ESI-MS) sample specifications. 
Sample # 4 5 6 7 


















In water water water water 
Molarity 100 uM 100 uM 100 uM 100 
uM 
Volume 50 uL 50 uL 50 uL 50 uL 
 
 In order to extract the valuable information from a raw ESI-MS spectrum, two 
equations need to be utilized to determine the mass and charge of the peaks present. To 
determine the mass, Equation 1 is used where M1 corresponds to the m/z value displayed 
on the spectrum for one ion, M2 corresponds to the m/z value displayed on the spectrum 
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for the adjacent lower ion, and A corresponds to the mass of the adduct which is typically 
a proton but could be a sodium or potassium ion. To determine the charge Equation 2 is 
used where z corresponds to the charge present for that peak or cluster of peaks, and all 
other variables follow the same as in      Equation 121. 
Equation 1. 
𝑀𝑊 =









 For the free PaIVY ESI-MS the molecular weight calculation is as follows 
corresponding to Figure 34. Each calculation was done following this example.  
 
𝑀𝑊 =
(1038 − 1)(968.9 − 1)
1038 − 968.9 = 	
(1037)(967.9)
69.1 = 14.525𝑘𝐷𝑎 
𝑧 = 	
968.9 − 1
1038 − 968.9 = 14	 
 
 Once the charges are determined for each cluster of peaks based on the raw data, 
this information can be used to calculate the average mass and differences in mass 
between shoulder peaks in the same charge cluster. This information indicates if there is 
an ion exchange happening at a given charge or if the warhead adduct is forming. The 
average masses are listed in Table 4 for each of the spectra indicating any adduct 
formation with its likely identity. For example, in Figure 34, it can be seen that there is a 
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shoulder peak to the right of the +15-charge peak. This peak has a given value of 986.8. 
Using this and the charge, the mass is calculated to be 14802 Da with a difference of 270 
Da from that of the free protein. This indicates that an adduct is forming on PaIVY 
reacted with [Re(CO)3(H2O)3]Br+ (1) at a molecular weight of approximately 270 Da. 
This was calculated for each of the peaks seen in Figure 38 with an average adduct mass 
of 269 Da. The warhead (1) adduct should have a mass of approximately 304 Da giving a 
difference of 35 Da or 35g. The solution that PaIVY was initially purified in was a 20 
mM potassium phosphate buffer. It was desalted into water, but due to the discrepancy of 
around 39 Da or 39 g/mol found on each of the spectra it is likely that there was still 
leftover potassium in the solution that was being exchanged in each of the samples. The 
approximately 35 g/mol discrepancy for the mass of the warhead (1) adduct is likely 
because there is a potassium ion lost when the warhead (1) is interacting with PaIVY.  











Mass of the 
adduct 
Identity of adduct 
PaIVY (Figure 37) - 14532 Da 14571 Da 39 Da Potassium ion 
[Re(CO)3(H2O)3]Br+ 
plus PaIVY (Figure 38) 
1 14532 Da 14801 Da 269 Da [Re(CO)3(H2O)3]Br+  
minus potassium ion  
[Re(CO)3(Phen)H2O]Br+ 
plus PaIVY (Figure 39) 
2 14531 Da 14573 Da 42 Da Potassium ion 
[Re(CO)3(Phen)]Cl+  
plus PaIVY (Figure 40) 
4 14531 Da 14570 Da 39 Da Potassium ion 
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Figure 35. Raw electrospray ionization mass spectrometry data of PaIVY plus 












  51 
 Figure 34 shows wild type PaIVY in water at 100uM. The spectrum indicates an 
average mass of 14532 Da. The most predominate charge for free PaIVY is +15 indicated 
by the largest relative peak followed by +16 and +14 respectively. There is a small peak 
for each charge cluster to the right which has an average mass of 14571 Da. It is likely 
that this small peak is from potassium ion exchange due to leftover potassium from the 
previous buffer. There are no other adducts forming therefore this spectrum is a good 
reference to compare the warhead (1) reacted ESI-MS spectra such as in Figure 35. 
Figure 35 shows wild type PaIVY reacted with [Re(CO)3(H2O)3]Br+ (1). The 
predominate charge is +15 followed by +16 and +14, the same as free PaIVY along with 
the average molecular weight remaining consistent. There is a shoulder peak on each of 
the charge clusters that is about half the size of the main peak for its respective charge. 
This peak is PaIVY plus the adduct with an average mass of 14801 Da. In this case the 
peak corresponds to [Re(CO)3(H2O)3]Br+ (1) attached to PaIVY indicating that this 
warhead (1) is binding to PaIVY. There is a slight mass discrepancy of 35 Da that is 
likely due to the missing potassium ion. Further to the right of this peak there is a slightly 
shorter peak belonging to the same charge cluster that has an average mass of 14839 Da 
making the adduct approximately 307 Da or 307g/mol which corresponds closely to that 
of the molecular weight of the warhead (1).  
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Figure 36. Raw electrospray ionization mass spectrometry data of PaIVY plus 
[Re(CO)3(Phen)H2O]Br+ in water at 100uM. 
 
 
Figure 37. Raw electrospray ionization mass spectrometry data of PaIVY plus 
[Re(CO)3(Phen)]Cl+ in water at 100uM. 
 
 Figure 36 shows PaIVY reacted with [Re(CO)3(Phen)H2O]Br+ (2) in water at 
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previous two spectra at 14.531kDa. The predominate charge is 15+ followed closely by 
+14 and +16 which differs from the spectrum of the free protein. This spectrum does 
have a lot of relatively small shoulder peaks, however none of them are predominant 
relative to that of the main peak in the charge cluster or correspond remotely close to the 
molecular weight of the warhead (2). This indicates that the warhead (2) is not binding. 
The failure for PaIVY to bind to this warhead (2) is likely due to the warhead (2) not 
being very soluble in water. Similarly, for Figure 37, it can be concluded that the 
warhead (4) is also not binding to PaIVY likely for the same reason due to the lack of any 
shoulder peaks that correspond to the molecular weight of the warhead (4). This spectrum 
has the same average mass of 14.531kDa, with the most predominate charge being +15 
followed by +16 and +14. The spectrum is almost identical to that of the free protein 
supporting the fact that the warhead (4) is not bound to PaIVY. There is only one small 
shoulder peak on this spectrum similar to that of free PaIVY which corresponds to a 
potassium ion exchange.  
 Based off the ESI-MS data, PaIVY is only readily reacting with 
[Re(CO)3(H2O)3]Br+ (1) and not the fluorescent warheads (2-4) containing 
phenanthroline. This data verifies that [Re(CO)3(H2O)3]Br+ (1) is reacting with PaIVY 
which was indicated by previous NMR experiments. However, this data did not indicate 
any dimer/trimer complexes forming, but this could be due to the molecular weight of 
those species being outside of the set parameters on the mass spectrometer. This data also 
supports the theory that Re(CO)3(Phen)Cl+ (4) and [Re(CO)3(Phen)H2O]Br+ (2) are not 
soluble enough in water to react with  PaIVY. This information is valuable in that it 
helped lead to the decision to react PaIVY with readily water soluble 
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[Re(CO)3(H2O)3]Br+ (1) first and then add phenanthroline to synthesize the desired 
warhead (3) PaIVY complex. 
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Chapter Six 
Conclusion and Future Work 
P. aeruginosa is a common threat to patients suffering from cystic fibrosis. These 
patients typically have a reduced lifespan and often die from respiratory failure caused by 
chronic bacterial lung infection with P. aeruginosa being a common contributor. It is 
often difficult to fight off a P. aeruginosa infection due to its antibiotic resistant biofilm 
production which may also be exacerbated by the secretion of a periplasmic protein, 
Inhibitor of Vertebrate Lysozyme, named after its inhibition of lysozyme PaIVY In order 
to inhibit the inhibitor a reactive warhead was designed and tested to see if mutating 
specific residues or adding the reactive warhead would ultimately allow lysozyme to 
effectively degrade the bacterium. Unfortunately based upon the data collected, mutating 
specific residues and the addition of the reactive warhead (3) did not have an effect on the 
inhibition PaIVY exhibits towards lysozyme suggesting that current models for how IVY 
inhibit lysozymes7 may need to be reexamined.  
Due to the potential impact inhibiting PaIVY could have, it has been worked on 
by multiple individuals. A previous graduate student designed the protein purification 
process that served as a basis for protein purification during this project, however 
modifications were made to increase efficiency in this new work. This protocol consists 
of an immobilized metal affinity chromatography nickel column His1, followed by a 
dialysis with TEV cleavage to remove the His tag. Next the protein is run over the nickel 
column a second time to separate the His tag from the protein. Subsequently the collected
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 fraction is concentrated and run over a size exclusion chromatography column to ensure 
purity of the correct protein. The only modification frequently used to his protocol was 
the use of a different buffer during the SEC to eliminate the need for a buffer exchange 
later. This modification is important because it allows for less time between protein 
purification and having the final concentrated protein available for experiments. This is 
especially important when reacting the protein with the any of the warheads as eventually 
proteins degrade so the less time spent concentrating the more time there is for 
experiments to be conducted with less of a chance of protein degradation. Primers were 
designed to mutate the histidine 62 residue of PaIVY to alanine, and PCR was completed 
for further investigation of this residue. This made it possible to observe the importance 
of the H62 residue of PaIVY in the inhibition of lysozyme using a muramidase assay as 
well as the importance of this residue when a reactive warhead is reacted with PaIVY.  
The initial warhead designed was [Re(CO)3(H2O)3]Br+ (1), which was easily 
water soluble. This compound did bind to PaIVY, but due to the formation of oligomers 
its binding location was unable to be successfully seen on an HSQC NMR spectrum. 
From here the warhead was redesigned to contain 1,10-phenanthroline (2-4) to block 
PaIVY from forming these oligomeric complexes with the warhead. Both 
[Re(CO)3(Phen)H2O]Br+ (2) and Re(CO)3(Phen)Cl+ (4) were poorly water soluble 
making it difficult to get an HSQC NMR spectrum or do any further experiments. In 
order to combat this obstacle, the easily water soluble [Re(CO)3(H2O)3]Br+ (1) was 
reacted with PaIVY and then 1,10-phenanthroline was added. In order to ensure only the 
monomer PaIVY in complex with the reactive warhead (3) was used for further 
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experiments a size exclusion chromatography column was utilized. This became the 
primary technique to form the reactive warhead (3) in complex with PaIVY.  
Once the design of the reactive warhead and optimization of the complex 
formation was achieved for the warhead (3), it became evident that this warhead was not 
binding to the proposed active site, H62. This was seen on the wild type 15N PaIVY 
HSQC NMR spectrum that when the protein was in complex with the warhead (3), 
majority of the residues that experienced chemical shift perturbation were located near 
H20. This was also confirmed on the H62A mutant 15N PaIVY HSQC NMR spectrum 
that there were still chemical shifts once the H62 residue was no longer available for 
binding. From this point site-directed mutagenesis was performed a second time to 
mutate the histidine 20 residue to aspartic acid. The H20D mutant NMR spectra indicated 
that H20 was experiencing little chemical shift perturbation but rather linebroadening 
when reacted with the warhead warhead (3). This was clearly noticed in residues G38 and 
S39 which were also residues that experienced chemical shift perturbation in the wild 
type PaIVY spectrum as well as the H62A mutant spectrum. This data indicated that H20 
alone was not the binding site for the warhead (3). It was proposed that perhaps a 
conformational change was occurring when binding occurs. The H20D/H62A double 
mutant NMR spectra confirms the theory that a conformational change is likely occurring 
because in this spectrum there is no chemical shift perturbation. It was also noted from 
this spectrum that some free protein did not react with the warhead (3). This is seen by 
peak splitting on the spectrum as well as on both wild type and mutant 15N PaIVY HSQC 
spectra.  
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Once it was identified where warhead (3) was likely binding, muramidase assays 
were performed for both wild type and all mutant PaIVYs with and without the addition 
of the warhead (3) in order to identify if these specific residues or the addition of this 
warhead had an effect on the inhibition of lysozyme. It was expected that wild type 
PaIVY in the presence of lysozyme, specifically HEWL, would cause the fluorescent 
signal to decrease at higher concentrations of PaIVY because the cells were not being 
lysed. The muramidase assay confirmed this trend. However, the same trend was seen for 
all mutant IVYs including H62A. This indicated that H62 may not be the only important 
residue in the inhibition of lysozyme and that the residues neighboring H62 on the 
exposed loop may also play a more important role in the inhibition than was previously 
suggested by the crystal structure of IVY bound to HEWL.7 The muramidase assays with 
the reactive warhead (3) also followed the same trend in which the fluorescence 
decreased at higher concentrations of PaIVY for all mutants and wild type indicating that 
warhead (3) was not binding to the correct site to block inhibition of lysozyme. However, 
it is possible that there is still too much free protein that is unreacted with the warhead (3) 
that was able to inhibit lysozyme. This hypothesis is supported by the fact that there were 
split peaks on the NMR spectra that showed not all of the protein was in complex with 
PaIVY, wild type or mutant. From this information it is difficult to conclude whether or 
not warhead (3) really has an effect on the inhibition of PaIVY there is no way to 
separate the free protein from the reacted protein. Resolving this ambiguity is important 
for future studies of this system. 
In the future there is still work that could be done to further understand where this 
warhead (3) is binding as well as how the inhibition of lysozyme if affected when the 
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warhead (3) is reacted with PaIVY. As suggested previously H62 may not be the only 
important residue in the inhibition of lysozyme. In order to fully understand the inhibition 
PaIVY exhibits towards lysozyme the residues neighboring His62, proline and aspartic 
acid, should be mutated individually as well in conjunction with each other. This would 
help indicate if all are responsible for the inhibition of lysozyme together. From here the 
previously done experiments should be repeated with these mutants to get a better 
understanding of the interaction with lysozyme as well as the effect the warhead (3) 
might have when these residues are mutated.  
Other mass spectrometry techniques would also be useful in identifying where the 
warhead (3) is binding precisely to PaIVY such as a hydrogen-deuterium exchange mass 
spectrometry (HDX-MS) experiment in conjunction with tandem mass spectrometry 
(MS-MS) experiment. In an HDX-MS experiment the binding site and interaction is 
revealed by monitoring the exchange rates between hydrogen and deuterium of the amide 
proton of the protein. Hydrogen atoms not involved in the protein-warhead interaction 
will exchange at a much more rapid pace than those involved in the interaction thus 
indicate where binding is occurring.22 These experiments should be done in order to 
provide valuable information indicating where the warhead (3) is binding and what 
residues are involved which has yet to be obtained concretely from the research thus far. 
Doing these experiments with the H62A, H20D, and H20D/H62A double mutant would 
verify that this warhead has some promiscuity when binding between the H20 and H62 
residues which can be addressed by experiments outlined further below.    
Additionally, it would be beneficial to do fluorescence polarization studies on 
PaIVY in complex with the warhead (3). Fluorescence anisotropy/polarization is a widely 
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used technique in which polarized light is sent through a sample and the degree to which 
the light is polarized is inversely proportional to the rate of molecular motion. A small 
ligand will have rapid free rotation and therefore emit largely depolarized light while a 
much larger molecule will have a limited rotation and therefore emit largely polarized 
light.23 When the light reaches the detector the degree of polarization can indicate if a 
ligand, or in this case the warhead (3) is bound and what percentage is bound to the 
protein. This technique has many advantages such as not requiring any separation of 
bound and free ligand, being nonradioactive,  carrying out in solution phase, and  
requiring relatively low volumes of sample making it an ideal technique to be used in 
order to determine what percentage of protein is bound to the warhead (3).23 This 
experiment should be done because it would indicate what percent of the warhead is 
bound to PaIVY. One of the issues discussed previously is that after collecting the 
monomer peak from the SEC of warhead (3) reacted PaIVY is that it is unknown how 
much free protein is still in solution left to react and inhibit lysozyme. Knowing how 
much free protein is left would give a good indication of how reactive this warhead (3) 
truly is in an aqueous environment.  
Furthermore, some of the previous work done with PaIVY by Aaron Schultz was 
finding various drug fragments that bind to PaIVY. It would be beneficial to be able to 
link these fragments with the warhead (3). Using the warhead (3) design outlined here, in 
the future variations of phenanthroline or bipyridine complexes, such as dihydroxy 
phenanthroline, can be used to help link previously identified drug fragments to the 
reactive warhead (3) as well as help increase the solubility of the molecule, which was 
one of the challenges in this project. Linking the warhead to previously identified drug 
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fragments would increase the rate of the reaction by increasing the binding affinity and 
specificity for the drug molecule towards PaIVY. There are many histidine containing 
molecules found in the cellular environment. By linking these fragments, the warhead 
will have a high specificity and be directed towards the target His62 residue rather than 
H20 or any other histidine containing molecules. It would be beneficial to choose a 
strong binding drug fragments near the H62 residue to link to the warhead in order to 
increase the likelihood that the warhead would bind to the H62 residue instead of the H20 
residue and therefore result in an irreversible inhibition of PaIVY. Linking the warhead to 
different drug fragments or multiple would give a better understanding of binding and the 
required residues for inhibition of lysozyme by PaIVY. 
 Lastly to expand on this research even further, an artificial sputum closely 
resembling that of the sputum found in the lung environment of Cystic Fibrosis patients 
should be used to understand how this warhead (3)  would behave in a more realistic 
environment. The artificial septum would contain many other cellular components found 
in the lung environment that may have histidine residues. By using a realistic 
environment, it would prove that once a full drug-molecule is created by linking the drug 
fragments and the warhead (3) that there is high specificity of the complex towards His62 
of PaIVY.  Using this medium would also give a better understanding of how the 
warhead complex would behave in an imperfect environment rather than a filtered 
aqueous buffer that was used in the research done thus far. 
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Appendix One 
 
Figure A1.1. IR [Re(CO)3(H2O)3]Br+ (1) 
 
 
Figure A1.2. 1H NMR [Re(CO)3(H2O)3]Br+ (1)
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Figure A1.3. 13C NMR [Re(CO)3(H2O)3]Br+ (1) 
 
Figure A1.4. IR [Re(CO)3(Phen)H2O]Br+ (2) 
















1H proton zg30 on ReCO3PhenH2OBrl 4.13.21
ReCO3phenH2OBr  1  1  C:\Bruker\400-NMR-data\tleeper
a. 
b. 
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Figure A1.5. a.) 1H NMR [Re(CO)3(Phen)H2O]Br+ (2) full spectra b.) Zoomed in 
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Figure A1.6. a.) 13C NMR [Re(CO)3(Phen)H2O]Br+ (2) full spectra b.) Zoomed in 
upfield 
b. 
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Figure A1.7. IR [Re(CO)3(Phen)]Cl+ (4)
 
Figure A1.8. 1H NMR [Re(CO)3(Phen)]Cl+ (4) 
 














1H proton zg30 on ReCO3PhenCl 4.13.21
ReCO3phenCl  1  1  C:\Bruker\400-NMR-data\tleeper
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Figure A1.9. 13C NMR [Re(CO)3(Phen)]Cl+ (4) 
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Vectorless Host: E. coli BL21DE3PlysS 
Plasmid: Pa3902 in PSpeedET vector 
Promoter: Pbad-Forward 
Antibiotic resistance: Kanamycin 
Induction: 0.1% (w/v) L-(+)-Arabinose @ OD600 0.4-0.6 
Extinction Coefficient: 31065 
Molecular Weight: 14.5 kDa 
pI: 5.69 
Buffer Conditions: 40 mM KPhos, 200 mM KCl pH 8.0 
Room temp stable 
Withstands freeze-thaw cycles 
Withstands de-salting into water
 
  





Bucket with ice       
 SOC media         
Plasmid            
 BL21DE3PLysS single shot cells 
2 kanamycin LB/Agar plates                     




1. Place BL21DE3PLysS single shot cells ampule and plasmid in ice bucket to thaw 
2. Place SOC media on benchtop from refrigerator to warm up 
3. Place all three LB/Agar plates in incubator at 37oC 
4. Once cells and plasmid are thawed, pipet 80 ng plasmid directly into cells and 
put cells back on ice for 30 minutes.  
5. Heat-shock for 42 seconds at 42oC 
6. Place back on ice to rest for 5 minutes 
7. Add 0.95mL SOC media to cells. Place in 37oC shaker @ 260 rpm for 1 hour 
8. Pipet 100 µL and 200 µL cells onto kanamycin plate and 200 µl onto ampicillin 
plate, spread onto plate evenly 
9. Incubate at 37o overnight 
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10. Parafilm and store in refrigerator. Shelf life ~ 2 weeks 
  














1. Pull transformation plates and set up loop assembly and Bunsen burner 
2. Sterilize loop until red hot, allow to cool. 
3. Loop 2-3 isolated colonies and stir into flask. Repeat for second flask 
4. Add 100 µL kanamycin stock to each flask.  
5. Cover top of flask with foil and place in shaker at 37oC overnight 
  





Two (2) autoclaved 2600 mL fernbach flasks with 1000mL sterile LB or M9 media 
2000 mL flask with 500 mL media may be used as a substitute. 
Flasks from small inoculum 
Spectrophotometer 
Plastic cuvettes 
Four (4) 0.5 g Arabinose single shots 




1. Turn on spectrophotometer  
2. Spike 1000 mL media with 1000µL kanamycin stock solution if applicable 
3. Reserve 1 mL of media as a blank. 
4. Pull small inoculum from the shaker, pour contents into fernbach flasks. 
Cover and shake to homogenize 
5. Pipet 1 mL into cuvette, record OD600. Induction OD600=0.4-0.6 mAU 
a. If OD600 is below 0.4, shake at 37oC for 20-minute intervals, taking 
OD600 readings at each interval until absorbance is 0.4-0.6. 
b. If OD600 is within range, move to step 6. 
6. Reserve 4-6 mL non-induced mixture and place in 15 mL falcon tube 
7. Induce with L-(+)-arabinose to 0.1%(w/v)  
0.1% (w/v) is 1 g arabinose per 1000 mL media 
8. Label flask and tape 15 mL non-induced control mixture to the fernbach flask 
9. Place in shaker at 37oC overnight 
 
Large Inoculum Centrifuge Protocol 
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Materials 
Sorvall RC6 plus super centrifuge 
F10-6X500Y Rotor from cold room 
500 mL centrifuge bottles with screw caps (6 for 2 L prep) 




1. Turn on centrifuge and place rotor inside unit, screwing lid onto rotor, then 
securing top screw into centrifuge. 
2. Quick-temp the centrifuge by setting rotor on screen. Start spin then immediately 
stop. This kickstarts the compressor. 
3. Set parameters to 8000 RPM at 15 minutes, 4oC 
4. Gather two 1 mL samples, induced and uninduced control, in eppendorf tubes 
5. Pour large inoculum culture into centrifuge bottles. Volume should be around 2/3 
height of bottle.  
6. Balance filled bottles against each other using Harvard balance. 
7. Place balanced bottles across from one another to balance rotor 
8. Secure lid to rotor 
9. Secure rotor to centrifuge 
10. Confirm rotor and spin settings 
11. Start and step back 
WARNING! ROTOR IS SUSCEPTIBLE TO FAILURE DURING 
ACCELERATION AND DECELERATION 
12. Pour off clear supernatant and store pellets in -20oC freezer 
13. Bleach supernatant and culture bottles for 20 minutes 
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1 L or 2 L graduated cylinder 
2.5 L beaker with stir bar 
Dibasic potassium phosphate 
Monobasic potassium phosphate 
Potassium chloride 
Imidazole 
Hydrochloric acid  
Potassium hydroxide 
Digital analytical balance 
Stir plate 
pH meter 




1. Place ~500 mL 18 MΩ deionized water in beaker with stir bar. Place beaker on 
stir plate 
2. Weigh ingredients using analytical balance 
3. Dissolve ingredients into water 
4. Adjust pH to 8.0 using pH meter and appropriate acid or base 
5. Pour into appropriate graduated cylinder and bring up to volume using 18 MΩ DI 
H2O 
6. Vacuum filter and degas buffer. 
7. Store Buffer A, Buffer B, and SEC buffer in clean 1L glass screw cap bottle 
8. Dialysis buffer may be stored in a 2.5 L Nalgene beaker covered with plastic wrap 
9. Apply appropriate label with name, date, product name, contents and pH.  
Example: AS 7/1/19 PaIVY Buffer A 40 mM KPhos 200 mM KCl, 20 mM imidazole 
pH 8 
10. Store in deli-style refrigerator  












































































































500 mL centrifuge bottles with pellets from large inoculum centrifugation 
20 mL buffer A 
60 mL homogenizer with plastic plunger 




1. Pour 20 mL buffer A into one centrifuge bottle with pellet. Vortex until pellet has 
completely loosened into the buffer. 
2. Pour off contents of bottle into next centrifuge bottle with pellet.  
3. Repeat steps 1-2 until all pellets have been loosened 
4. Pour contents into homogenizer and place in ice 
5. Use plunger with an up/down and twisting motion to homogenize cells into buffer 
A. Product should be a uniform, creamy, light tan solution 
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French Press 
 
CAUTION! VERY DANGEROUS. USES A COMBINATION OF HIGH 
PRESSURE FROM AN OPEN HYDRAULIC PRESS AND 10 kg STEEL 
CELL. SEVERE INJURY MAY OCCUR WITH IMPROPER USE.  
Materials 
 
open hydraulic french press 
french press cell with T-bar plunger 
homogenized cell culture 
500 mL beaker with ice 




1. Ensure new french press machine is set to “down” and “pause”. Turn on machine 
2. Lubricate rubber on plunger with petroleum jelly and assemble cell body with T-
bar plunger to “MAX FILL” line 
3. Place upside down onto cell stand 
4. Assemble base of cell with outlet nozzle and flow restrictor screw tightened 
5. Pour homogenized sample into cell body. Make sure to leave about 3 cm of room 
for the cell base. 
6. Place cell base onto cell body and invert to right side up.  
7. Place assembled cell into press with the T-bar above the T bar plunger notches. 
Cell should be positioned with the plastic button on the cell body in line with the 
steel screw rod, outlet nozzle facing forward, and flow restrictor screw easily 
accessed to the left.  
8. Secure cell in place using steel cross bar with screw assembly.  
9. Attach outlet nozzle hose 
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10. Set to “LOW” and “RUN”. Allow pressure to stabilize (~1750 PSI). Make sure 
cell has not moved from its restraints and that the T-bar has made flush contact 
with the top plate. You should not see any flow through the outlet hose. 
11. Set to “HIGH”. Allow pressure to stabilize. You should not see flow through the 
outlet hose. 
12. Using the small mallet, tap the flow restrictor screw in a counter-clockwise 
fashion until a slow flow is seen in the outlet hose. 
13. Once flow has reached the end of the outlet hose, regulate the flow to 1-2 drops 
per second into a small centrifuge bottle. Contents in the hose should look like a 
dark tan liquid with cream liquid on top.  
14. Run until the plunger reaches “STOP”. Set machine to “PAUSE” 
15. Set machine to “DOWN” and “RUN”. 
16. Repeat steps 3-15 two times.  
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Sorvall RC6 plus super centrifuge  
F21S 8X50Y centrifuge rotor from cold room 
Crude lysate from french press 




1. Turn on centrifuge  
2. Input run conditions 18000 RPM, 45 Min, 4oC 
3. Install rotor fastening lid first by tightening bottom screw, then top screw 
4. Select rotor 
5. Quick start compressor by starting and immediately stopping run 
6. Balance samples using Harvard balance 
7. Place samples in centrifuge directly across from one another (i.e. slots 1 and 5) 
8. Fasten bottom screw and top screw to rotor 
9. Confirm run conditions and rotor selection 
10. Start and step back.  
 
WARNING! ROTOR IS SUSCEPTIBLE TO FAILURE DURING 
ACCELERATION AND DECELERATION 
 
11. After run is complete immediately pour off supernatant into a 50 mL falcon tube. 
12. Take a 100µL sample of the supernatant placing it in a 1.5mL epi tube. Label 
CRUDE 
13. Inspect pellet. The outside edge of the pellet should be glassy and transparent. 
This represents cell membrane fragments. As you inspect closer to the center, the 
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color should be tan with a dark bullseye representing heavier bacterial cell 
fragments.  




1. System pump buffer selection icon for pump A and pump B 
a. Allows to change between buffers using valve 
2. System pump operation icon 
a. Allows pump A and B operation. Isocratic or gradient. 
3. Sample pump operation icon 
a. load and/or inject sample  
4. Sample pump flow selection icon 
a. Changes selection to loop or direct column  inject for sample pump and 
system pump 
5. Column selection icon 
a. changes flow to selected column 
6. Column 
7. UV/Connectivity icon 
a. toggle lamps on/off, zero absorbance readings 
8. Fraction collection icon 
a. set collection tube parameters- type/volume/amount 
9. Waste icon  
  86 
1st Ni-column (His-1) Purification by Immobilized Metal Affinity Chromatography 
(IMAC) 
 
The purpose of this purification step is to separate our protein from the rest of the 
bacterial proteins by leveraging the utility of the 6 histidine tag. When the crude lysate 
flows across the nickel column, the nickel binds PaIVY which contains a his tag. Low 
imidazole concentration running buffer that flows over the column in the next step helps 
kick off weakly binding proteins. High concentration imidazole in an elution buffer 
knocks PaIVY off of the nickel column. There are a few important cautionary steps 
whenever purifying protein on the NGC. First, make sure you do not introduce any air 
into the system.Introducing air into a column can dry out the column matrix and destroy 
the column. Second, make sure flow is within operating range for the column you are 
using. Using a flow rate too high for a column will compress the matrix and destroy the 
column. Third, ensure that the fraction collector is turned on and is connected to the NGC 
before loading your protein. If the fraction collector is not communicating with the NGC, 
the entire system must be restarted. Finally, once the protein is loaded, do not zero out the 




NGC liquid chromatography system running ChromLab program 
PaIVY buffer A (see page 8) placed in buffer selector 3A 
PaIVY buffer B (see page 8) placed in buffer selector 3B 
Centrifuged crude lysate 
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Methods 
 
1. Equilibrate the Ni-column. 
a. Set column selection icon to slot 1 
b. Run DI water (system pump buffer selector slot 2) at 5 mL/min for 25 mL 
c. Run buffer B (system pump buffer selector slot 3 100%B) @ 5mL/min 25 
mL 
d. Run buffer A (system pump buffer selector slot 3 0%B) @5mL/min 25 
mL, zeroing out the absorbance under UV/Conn icon within 5 mL of 
completion 
e. set column selection icon to bypass 
f. set sample pump flow selection to “Sample pump direct inject, system 
pump waste.” line on computer diagram should be light blue from the 
sample pump through the column and into waste. 
g. using sample pump, direct inject 10 mL buffer A to clear out sample 
pump. 
h. turn column selection icon back to position 1 
i. clear out run. 
2. Load the crude lysate 
a. take the empty 50 mL falcon tube labelled “flow through” and place in 
plastic waste jug with lines in the falcon. The tube should not fall through 
into the bottom. it should sit on the lid of the waste collector. 
b. determine volume of centrifuged lysate and set injection volume of sample 
pump. 
c. place falcon tube into clamp by sample pump. Insert brown sample 
loading tube to the bottom of the falcon. 
d. load sample using sample pump at 5 mL/min. stop pump just before all 
sample is gone. you should see a large plateau on the chromatogram.  
e. add approximately 10 mL buffer A at 5 mL/min to residual crude lysate 
and run sample pump for <10 mL to ensure injection of all crude lysate.  
f. remove “flow through” falcon tube from the waste container 
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g. switch sample pump flow selection to “Manual inject loop, system pump 
to column.” Flow line on computer diagram should show a red injection 
loop and a green line running from the system pump through the column 
and to waste. 
3. Set up fraction collection 
a. ensure fraction collector is on, has clean racks in it, and is connected to the 
system. 
b. click on the blue fraction collector viewer icon and press both “remove 
empty racks” and “remove all” 
c. close out window 
d. double click on fraction collector to open window. Rack type should be  
F1 (12-13 mm X 100mm tubes) Start collection from A1 and end at B90. 
Fraction size should be 4 mL. 
4. Achieve adequate separation. 
a. Set system pump to 5 mL/min, 0% B, for 25 mL. Start pump 
b. turn on fraction collection by double clicking fraction collector and 
pressing “collect.” you are now collecting fractions. 
c. absorbance line should be near or at baseline after 25 mL run. if not, run 
10 mL at a time until the baseline of A280 is less than 50 mAU 
5. Elute PaIVY from the column. 
a. Under the system pump, choose gradient, initial %B 0%, final %B 100%, 
25 mL then click the check box to run final B% for an additional 15 mL. 
b. Start flow. you should start to see a peak around 30%B 
c. at 100%B, you will notice that A280 flattens out around 300 mAU. To 
establish this is absorbance from the high concentration imidazole, run 15 
mL 0%B and watch the absorbance line and the connectivity line. the line 




6. Finishing up 
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a. Stop collection 
b. press “reset arm” 
c. collect fractions from peak in 50 mL falcon labelled “peak fraction” 
d. add 1:1000 EDTA to peak fraction falcon. 
i. if you collected 16 mL sample, add 16µL EDTA 




f. close out run and open up analysis 
g. deselect every line trace except A280, %B, and connectivity 
h. Create run report under File 
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Dialysis and TEV cleavage 
 
The purpose of this step is to remove excess imidazole from the peak fractions to allow 




Pooled peak fractions containing 0.5 mM (1:1000 dilution) Disodium EDTA from 0.5 M 
stock 
TEV 
3500 MW Snakeskin® dialysis tubing with green tube clamps 




1. Soak a strip of 3500 MW Snakeskin® dialysis tubing in dialysis buffer to hydrate 
dialysis membrane 
2. Fold the first end of the dialysis tubing in a “greek key” motif by making one 
large fold, then folding the large fold in half. clamp the folded membrane with a 
green clip. 
3. Using a disposable pipet, transfer the pooled fraction containing EDTA into the 
dialysis tubing. Clamp the second end of the tubing using the same folding 
technique. make sure there is an air bubble in the dialysis tubing, allowing the 
tubing to float in the dialysis buffer.  
4. Place dialysis tubing in dialysis buffer for at least 3 hours to reduce the imidazole 
concentration in the pooled fractions. 
5. After dialysis, transfer the dialyzed protein into a clean 50 mL falcon tube. 
6. add TEV at a ratio of 1 part TEV to 50 parts protein. (eg. if you have 50 mg 
PaIVY, add 1 mg of TEV) 
7. set on benchtop overnight  
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2nd Ni-column (His-2) Purification by Immobilized Metal Affinity Chromatography 
(IMAC) 
 
The purpose of this purification step is to further purify your protein by separating the 
cleaved PaIVY protein from the TEV,  N-terminal his-tag, and any non-specific binding 
proteins that co-eluted with PaIVY during the first nickel column. We use a cleave and 
clear strategy to remove the his tag from our protein. By running our protein over a nickel 
column a second time, the flow through will contain PaIVY and the His tag along with 




NGC liquid chromatography system running ChromLab program 
PaIVY buffer A (see page 8) placed in buffer selector 3A 
PaIVY buffer B (see page 8) placed in buffer selector 3B 
Dialyzed PaIVY with TEV 




1. Equilibrate the Ni-column. 
j. a.Set column selection icon to slot 1 
k. Run DI water (system pump buffer selector slot 2) at 5 mL/min for 25 mL 
l. Run buffer B (system pump buffer selector slot 3 100%B) @ 5mL/min 25 
mL 
m. Run buffer A (system pump buffer selector slot 3 0%B) @5mL/min 25 
mL, zeroing out the absorbance under UV/Conn icon within 5 mL of 
completion 
n. set column selection icon to bypass 
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o. set sample pump flow selection to “Sample pump direct inject, system 
pump waste.” line on computer diagram should be light blue from the 
sample pump through the column and into waste. 
p. using sample pump, direct inject 10 mL buffer A to clear out sample 
pump. 
q. turn column selection icon back to position 1 
r. clear out run. 
7. Load the PaIVY and TEV sample 
a. take the empty 50 mL falcon tube labelled “His 2 Peak Fraction” and 
place in plastic waste jug with lines in the falcon. The tube should not fall 
through into the bottom. it should sit on the lid of the waste collector. 
b. determine volume and set injection volume of sample pump. 
c. place falcon tube into clamp by sample pump. Insert brown sample 
loading tube to the bottom of the falcon. 
d. load sample using sample pump at 5 mL/min. stop pump just before all 
sample is gone. you should see a large plateau on the chromatogram.  
e. add approximately 10 mL buffer A at 5 mL/min to residual protein and 
run sample pump for <10 mL to ensure injection of all protein. 
f. remove “His 2 peak fraction” falcon tube from the waste container. this is 
where your protein is.  
g. switch sample pump flow selection to “Manual inject loop, system pump 
to column.” Flow line on computer diagram should show a red injection 
loop and a green line running from the system pump through the column 
and to waste. 
8. Set up fraction collection 
a. ensure fraction collector is on, has clean racks in it, and is connected to the 
system. 
b. click on the blue fraction collector viewer icon and press both “remove 
empty racks” and “remove all” 
c. close out window 
d. double click on fraction collector to open window. Rack type should be  
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F1 (12-13 mm X 100mm tubes) Start collection from A1 and end at B90. 
Fraction size should be 4 mL. 
 
 
9. Achieve adequate separation. 
a. Set system pump to 5 mL/min, 0% B, for 25 mL. Start pump 
b. turn on fraction collection by double clicking fraction collector and 
pressing “collect.” you are now collecting fractions. 
c. absorbance line should be near or at baseline after 25 mL run. if not, run 
10 mL at a time until the baseline of A280 is less than 100 mAU 
10. Elute His tag and TEV from the column. 
a. Under the system pump, choose gradient, initial %B 0%, final %B 100%, 
25 mL then click the check box to run final B% for an additional 15 mL. 
b. Start flow. you should start to see a peak around 30%B 
c. at 100%B, you will notice that A280 flattens out around 300 mAU. To 
establish this is absorbance from the high concentration imidazole, run 15 
mL 0%B and watch the absorbance line and the connectivity line. the line 
shapes should be very similar. A280 should drop down close to zero. 
11. Finishing up 
a. Stop collection 
b. press “reset arm” 




d. close out run and open up analysis 
e. deselect every line trace except A280, %B, and connectivity 
f. Create run report under File 
g. save in a folder created on desktop.  
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Size Exclusion Chromatography (SEC)  purification  
 
The purpose of this step is to ensure that the protein collected from the previous 
purification steps is pure, and is the molecular weight expected for PaIVY. This column 
is much more fragile than the IMAC columns. Maximum flow through these columns is 
0.5-0.7 mL/min. minimum volume required to equilibrate column is 120 mL so plan 
accordingly. If the column is stored in ethanol, it will require 120 mL of water, then 120 




NGC liquid chromatography system running ChromLab program 
PaIVY SEC buffer (see page 8) placed in buffer selector 6 
His-2 purified peak fraction concentrated to under 5 mL. 




1. Ensure SEC column (column selector 5) is equilibrated to PaIVY SEC buffer 
(buffer selector 6) and baseline is zeroed.  
2. direct inject the His-2 purified, concentrated PaIVY onto the SEC column at 0.5 
mL/min 
3. Change the sample pump flow selector to “system pump to column, sample pump 
direct inject” 
4. Set system pump for 0%B 120 mL at 0.5 mL/min and start the pump. 
5. Immediately start fraction collection (4 mL) 
6. PaIVY will come off the column around 80 mL. 
7. Pool the peak fractions into the 50 mL falcon tube labeled SEC purified PaIVY 
and store in deli-style refrigerator.  
8. Save run. 
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